AngioDynamics (ANGO) vs Sight Sciences (SGHT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sight Sciences (SGHT) has outperformed AngioDynamics (ANGO) over the past year, gaining 40.2% versus a loss of 9.5%. Over five years, SGHT leads with a -46.7% price change compared with -60.3% for ANGO. Sight Sciences is the larger company by market cap ($565.8 million vs $454.6 million), about 1.2 times the size, while AngioDynamics is growing revenue faster (+9.5% vs -3.1%).
AngioDynamics converts more of its revenue into profit, with a net margin of -11.5% versus -49.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANGO | SGHT |
|---|---|---|
| Share price | $10.81 | $10.18 |
| Market cap | $454.61M | $565.79M |
| 1-day change | +0.46% | -4.14% |
| YTD return | -15.81% | +28.37% |
| 1-year return | -9.54% | +40.22% |
| 5-year return | -60.29% | -46.67% |
| EPS (TTM) | $-0.78 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $320.17M | $77.36M |
| Revenue growth (YoY) | +9.46% | -3.13% |
| Net income (latest FY) | $-36.74M | $-38.43M |
| Gross margin | 54.62% | 86.17% |
| Operating margin | -12.47% | -47.95% |
| Net margin | -11.48% | -49.67% |
| 52-week high | $16.29 | $11.60 |
| 52-week low | $9.39 | $3.38 |
| Distance from 52-week high | -33.64% | -12.20% |
| Analyst consensus | none | buy |
| Avg. price target upside | +82.70% | +20.33% |
| Average volume | 651.16K | 313.51K |
| Shares outstanding | 42.05M | 55.58M |
| Employees | 632 | 186 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SGHT has outperformed ANGO by 49.8 percentage points over the past year.
- AngioDynamics is more profitable, keeping -11.5 cents of every revenue dollar as net income versus -49.7 cents for Sight Sciences.
- AngioDynamics grew revenue faster in its latest fiscal year (+9.46% vs -3.13%).
About AngioDynamics
ANGO stock →AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments.
Health Care · Medical/Dental Instruments · 632 employees
About Sight Sciences
SGHT stock →Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye.
Health Care · Medical/Dental Instruments · 186 employees
ANGO vs SGHT FAQ
Which is bigger, AngioDynamics or Sight Sciences?
Sight Sciences (SGHT) is larger, with a market capitalization of $565.79M compared with $454.61M for AngioDynamics (ANGO).
Which stock has performed better over the past year, ANGO or SGHT?
SGHT returned +40.22% over the past 12 months, compared with -9.54% for ANGO (price return, excluding dividends). Past performance does not predict future results.
Are AngioDynamics and Sight Sciences in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.